|Potential drug interactions and duplicate prescriptions among cancer patients|
RP Riechelmann, IF Tannock, L Wang, ED Saad, NA Taback, ...
Journal of the National Cancer Institute 99 (8), 592-600, 2007
|A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients|
F Jadu, L Lee, M Pharoah, D Reece, L Wang
Annals of Oncology 18 (12), 2015-2019, 2007
|Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial|
TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ...
Genome medicine 8 (1), 1-12, 2016
|Evolution of the randomized controlled trial in oncology over three decades|
CM Booth, DW Cescon, L Wang, IF Tannock, MK Krzyzanowska
Journal of Clinical Oncology 26 (33), 5458, 2008
|Potential drug interactions in cancer patients receiving supportive care exclusively|
RP Riechelmann, C Zimmermann, SN Chin, L Wang, A O'Carroll, ...
Journal of pain and symptom management 35 (5), 535-543, 2008
|Expression analysis of 6p22 genomic gain in retinoblastoma|
M Orlic, CE Spencer, L Wang, BL Gallie
Genes, Chromosomes and Cancer 45 (1), 72-82, 2006
|Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of …|
AJ Templeton, FE Vera-Badillo, L Wang, M Attalla, P De Gouveia, ...
Annals of oncology 24 (12), 2972-2977, 2013
|Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours|
HJ Mackay, H Hirte, T Colgan, A Covens, K MacAlpine, P Grenci, L Wang, ...
European Journal of Cancer 46 (9), 1573-1579, 2010
|Hyperprogressive disease in early‐phase immunotherapy trials: clinical predictors and association with immune‐related toxicities|
Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ...
Cancer 125 (8), 1341-1349, 2019
|A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly …|
NG Chau, SJ Hotte, EX Chen, SF Chin, S Turner, L Wang, LL Siu
Annals of oncology 23 (6), 1562-1570, 2012
|Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial|
S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ...
The Lancet 397 (10271), 281-292, 2021
|Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma|
S Lheureux, MO Butler, B Clarke, MC Cristea, LP Martin, K Tonkin, ...
JAMA oncology 4 (7), e173776-e173776, 2018
|Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2|
LT Nguyen, SD Saibil, V Sotov, MX Le, L Khoja, D Ghazarian, L Bonilla, ...
Cancer Immunology, Immunotherapy 68, 773-785, 2019
|Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials|
B Seruga, L Sterling, L Wang, IF Tannock
Journal of clinical oncology 29 (2), 174-185, 2011
|Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas|
A Stathis, SJ Hotte, EX Chen, HW Hirte, AM Oza, P Moretto, S Webster, ...
Clinical Cancer Research 17 (6), 1582-1590, 2011
|A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial|
HW Hirte, L Vidal, GF Fleming, AK Sugimoto, RJ Morgan, JJ Biagi, ...
Journal of Clinical Oncology 26 (15_suppl), 5521-5521, 2008
|Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma|
M Velec, CR Haddad, T Craig, L Wang, P Lindsay, J Brierley, A Brade, ...
International Journal of Radiation Oncology* Biology* Physics 97 (5), 939-946, 2017
|The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell …|
NG Chau, B Perez-Ordonez, K Zhang, NA Pham, J Ho, T Zhang, ...
Head & neck oncology 3, 1-11, 2011
|Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer|
PA Tang, SJ Cohen, C Kollmannsberger, G Bjarnason, K Virik, ...
Clinical Cancer Research 18 (21), 6023-6031, 2012
|A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium|
SS Sridhar, E Winquist, A Eisen, SJ Hotte, E McWhirter, IF Tannock, ...
Investigational new drugs 29, 1045-1049, 2011